Health Canada Begins Rolling Review of Medicago’s COVID-19 Vaccine
Health Canada has launched a rolling review of Medicago’s two-dose COVID-19 vaccine candidate that is currently being evaluated in a phase 3 trial.
The plant-based vaccine contains a recombinant spike glycoprotein that mimics the SARS-CoV-2 virus in order to induce a protective immune response to the virus. It also features an adjuvant supplied by GlaxoSmithKline.
The late-stage study aims to enroll up to 30,000 individuals across 10 countries. The trial’s completion date is set for the end of April 2022, according to ClinicalTrials.gov.